[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507083":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":37,"collaborators":39,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":7,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":7,"enrollmentInfo":52,"targetDuration":55,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":67,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"The University of Hong Kong","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Harinder Gill, MD","PRINCIPAL_INVESTIGATOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+852 22554542","gillhsh@hku.hk",[18],{"facility":19,"status":20,"city":21,"state":7,"zip":7,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"Department of Medicine, Queen Mary Hospital","RECRUITING","Hong Kong","HK",{"type":24,"coordinates":25},"Point",[26,27],114.17469,22.27832,{"lat":27,"lon":26},[30,31,32,35],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"name":33,"role":34,"phone":7,"phoneExt":7,"email":7},"Garret Leung, MD","SUB_INVESTIGATOR",{"name":36,"role":34,"phone":7,"phoneExt":7,"email":7},"Yok-lam Kwong, MD",{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[40],{"name":41,"class":42},"Novartis","INDUSTRY","100507083","asian-myeloproliferative-neoplasm-mpn-registry-100507083",false,"NCT05882773","Asian Myeloproliferative Neoplasm (MPN) Registry","Asian Myeloproliferative Neoplasm (MPN) Registry - An Asian Myeloid Working Group (AMWG) Project.","Inclusion Criteria:\n\n1. Age ≥ 18 years old at the time of diagnosis of MPN.\n2. Subject was diagnosed with one of the following disorders according to the 2017 WHO classification (for patients diagnosed before 2017, the bone marrow reports will be re-evaluated according to the 2017 WHO classification):\n\n   1. Polycythaemia vera\n   2. Essential thrombocythemia\n   3. Primary myelofibrosis, pre-fibrotic\u002Fearly stage\n   4. Primary myelofibrosis, overt fibrotic stage\n   5. Post-polycythaemia vera myelofibrosis\n   6. Post-essential thrombocythaemia myelofibrosis\n   7. MPN-unclassifiable\n3. All subjects need to provide informed consent.\n\nExclusion Criteria:\n\nA subject will not be eligible if he\u002Fshe meets any of the following criteria:\n\n1\\. Subject was diagnosed with myelodysplastic syndrome, myelodysplastic syndrome\u002Fmyeloproliferative neoplasm, or chronic myeloid leukaemia BCR-ABL1 positive, under the 2017 WHO classification","ALL","18 Years",{"count":53,"type":54},1000,"ESTIMATED","10 Years","OBSERVATIONAL","This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.",[59,60,61,62,63,64,65,66],"Myeloproliferative Neoplasm","Polycythemia Vera","Essential Thrombocythemia","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis","Primary Myelofibrosis","Primary Myelofibrosis, Prefibrotic Stage","Primary Myelofibrosis, Fibrotic Stage",[68,69,70,71],"Myeloproliferative neoplasm","Epidemiology","Outcome","Prognostic factors","2023-05-21",{"date":74,"type":75},"2023-05-31","ACTUAL",{"date":77,"type":54},"2023-05",{"date":79,"type":54},"2026-12",{"name":5,"class":6},1]